AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00846924 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a 30-day ambulatory cardiac event monitor
Description: Patients will be fitted with dry electrode belt (including cardiac event monitor)and instructed to wear the device for as many hours(waking and sleeping) each day as possible, for a total of 30 days.
Study NCT00846924 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 24-hour Holter
Description: Repeat standard 24-hour Holter Monitor
Study NCT01403207 — intervention group
Intervention type: OTHER
Intervention: musculoskeletal
Description: Many musculoskeletal conditions are impacted by the chromosomal sex of the patient. While osteoarthritis (OA) is predominant in men younger than 50 years of age, after age 50 the condition is more prevalent in women, particularly post-menopause. This has implications for diagnosis and treatment of OA, as well as for joint replacement.
Study NCT01697657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily in the morning and at bedtime for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2
Study NCT01697657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin NPH
Description: Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily in the morning and at bedtime for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2
Study NCT01697657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily before meals for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2
Study NCT01697657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily before meals for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2
Study NCT04502745 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Cortical Access System (MICAS)
Description: Temporary surgical tool that provides access to the sub-dural space through the cranium.
Study NCT04038723 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Description: Cardiac patients have completed 36 times of exercise training with the exercise frequency of 2-3 times per week. Subjects performed five 3-minute intervals at 80% of VO2peak and each interval was separated by 3-minute exercise at 40% of VO2peak after the warm-up period. The exercise session was terminated by 3-minute cool-down at 30% of VO2peak.
Study NCT04428619 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral Electrical Nerve Field Stimulation (PENFS) Device
Description: Patients will complete daily worst abdominal pain and bowel habit questionnaires for 1 week prior to initial PENFS device placement to provide a baseline. At visit 1, patients will complete the Bowel Symptom Questionnaire, IBS Symptom Severity Scale (IBS-SSS), PROMIS Belly Pain Scale, Gas and Bloating, Constipation, and Diarrhea Scales, Hospital Anxiety and Depression Scale, and Visceral Sensitivity Index, heart rate variability will be measured, and they will have the initial PENFS device placed. Patients will complete daily worst abdominal pain (scale 0-10) questionnaires throughout the duration of the study. They will return every 7 days for a total of 4 visits for device replacement and additional questionnaires, including the IBS-SSS. Four devices will be placed in total (start of weeks 1, 2, 3, and 4). Stimulation time is 5 days/week during each of the 4 consecutive weeks. Additional questionnaires will be completed at the end of week 4 and at extended follow-up (8 weeks).
Study NCT04428619 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Description: Patients will complete daily worst abdominal pain and bowel habit questionnaires for 1 week prior to initial sham device placement to provide a baseline. At visit 1, patients will complete the Bowel Symptom Questionnaire, IBS Symptom Severity Scale (IBS-SSS), PROMIS Belly Pain Scale, Gas and Bloating, Constipation, and Diarrhea Scales, Hospital Anxiety and Depression Scale, and Visceral Sensitivity Index, heart rate variability will be measured, and they will have the initial sham device placed. Patients will complete daily worst abdominal pain (scale 0-10) questionnaires throughout the duration of the study. They will return every 7 days for a total of 4 visits for device replacement and additional questionnaires, including the IBS-SSS. Four devices will be placed in total (start of weeks 1, 2, 3, and 4). Stimulation time is 5 days/week during each of the 4 consecutive weeks. Additional questionnaires will be completed at the end of week 4 and at extended follow-up (8 weeks).
Study NCT03966599 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pain
Description: Patient's pain in order to VAS
Study NCT03966599 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Hemodynamic changes
Description: changes in hemodynamic states
Study NCT01693393 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclosporine A
Description: Patients will receive Cyclosporine A in a dose of ca. 2mg/kg/BW daily for a 16 week period
Study NCT01295619 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-020805
Description: A thin layer of I-020805 applied up to two times on the sutured dura mater
Study NCT02275806 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Irinotecan
Study NCT02275806 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Study NCT03331276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BBN
Description: BBN to be feed as the sole source of nutrition for 16 weeks to healthy term infants for 16 weeks.
Study NCT03331276 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brand
Description: Brand to be feed as the sole source of nutrition for 16 weeks to healthy term infants for 16 weeks.
Study NCT03185858 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SINEMA intervention
Description: Provider-facing intervention includes the following components:~(1) Systematic cascade training for village doctors; (2) monthly follow-up visits with the support of the SINEMA APP; (3) village doctor group activities; (4) performance feedback and incentives.~Stroke survivor-facing intervention program includes the following components:~(1) Briefing session; (2) monthly follow-up visits and follow-up handout; (3) daily voice message for health education.
Study NCT00110279 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca)
Description: Live attenuated H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine
Study NCT00758524 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Eplerenone-matching Placebo
Description: Eplerenone-matching placebo oral capsules
Study NCT03991325 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: upper airway sonography
Description: clinical evaluation of upper airway, ultrasonographic assessement
Study NCT00996905 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable ultrasound machine
Description: Each patient will have their lumbar spine scanned by ultrasound for a maximum period of 5 minutes.
Study NCT01476137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: MEK inhibitor
Study NCT03678246 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ramped position
Description: LSFOI glottis view
Study NCT03678246 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ramped position
Description: LSFOI glottis view
Study NCT03678246 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supine position
Description: LSFOI glottis view
Study NCT01476137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2110183
Description: AKT inhibitor
Study NCT03678246 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supine position
Description: LSFOI glottis view
Study NCT03839420 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CZM IOL
Description: implantation of CZM IOL
Study NCT03839420 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Competitor IOL
Description: implantation of Competitor IOL
Study NCT04700670 — intervention group
Intervention type: BIOLOGICAL
Intervention: measurement of anti-Xa activities
Description: The measurement of anti-Xa activities will be carried out on frozen-defrosted plasma citrate and CTAD with 4 reagents~* STA-Liquid anti-Xa (STAGO) (not containing dextran)~* Biophen Heparin LRT (Hyphen) (reactive containing dextran)~* Berichrom (Siemens) with dextran~* Berichrom (Siemens) without dextran~The dosage of platelet factor 4 and of the beta-TG will be carried out on frozen-defrosted plasma with the asserachrom PF4 and Asserachrom beta-TG (Diagnostica Stago) kits.
Study NCT04433897 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: All women fulfilled 3 questionairres~* TANGO~* ICIQ -N~* Perceived Stress Scale
Study NCT01850901 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal sympathetic denervation
Study NCT05666648 — intervention group
Intervention type: OTHER
Intervention: Sitz Bath
Description: Individual patients were randomized to either receive 'sitz baths' or 'no sitz baths' treatment for 4 weeks. Patients were asked to have 'sitz bath' once in morning and again at bedtime, after each week pain scores and healing of fissure were assessed. Main outcome measures were validated
Study NCT03359655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Rectal administration 2 jours before the procedure
Study NCT03359655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyoscine butyl bromide
Description: Rectal administration 2 jours before the procedure
Study NCT02222922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06647020 Q3W
Description: Part 1: PF-06647020 will be administered intravenously every 21 days in cohorts of 2-4 patients starting at a dose of 0.20mg/kg. Increases in dose will continue until MTD is determined.~Part 2: Patients with triple negative breast cancer (pre-selected for PTK7 moderately high to high expression), non small cell lung cancer (pre-selected with moderate to high PTK7 expression) and ovarian cancer patients (unselected for PTK7 expression) will be treated at the MTD or Recommended Phase 2 Dose selected in Part 1.
Study NCT02222922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluconazole
Description: combination drug used for drug-drug interaction sub-study
Study NCT02222922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06647020 Q2W
Description: Part 1: PF-06647020 will be administered intravenously every 14 days in cohorts of 2-4 patients starting at a dose of 2.1 mg/kg. Increases in dose will continue until MTD is determined.~Part 2: Patients with non-small cell lung cancer (pre-selected for PTK7 moderate to high expression and ovarian cancer patients (unselected for PTK7 expression) will be treated at the MTD or Recommended Phase 2 Dose selected in Part 1.
Study NCT02222922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06647020 combined with Avelumab
Description: Part 2: Patients with ovarian cancer (unselected for PTK7 expression) will be treated with PF-0664702 plus Avelumab.
Study NCT00098839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-asparaginase
Description: Given IM
Study NCT00478062 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hodgkin's antigens-GM-CSF-expressing cell vaccine
Study NCT00098839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00478062 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study NCT00098839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone
Description: 40 mg/m2/day PO divided BID or TID
Study NCT02070965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFD01 Spray
Study NCT02070965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comp01 Lotion
Study NCT03277443 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computer guided surgery
Description: Preoperative surgical simulation and immediate postoperative evaluation will be carried out using Multi Slice CT scan.Craniofacial images from 3D computerized tomography (3D-CT scan) can be used to create a 3D model, which can in turn be used for 3D Cephalometry measurements and surgical simulation.The process of 3D-model contains mounting of 3D virtual models in a 3D virtual articulator; and repositioning of 3D virtual models according to the STO then Fabrication of a 3D virtual intermediate surgical wafer; and materialization of the surgical wafer using a stereolithographic technique. The 3D model can produce actual movement of surgical cuts and movement of segments accordingly
Study NCT03277443 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional model surgery
Description: preparation for orthognathic surgery which involves diagnosis with 2D cephalometric radiograph, face-bow transfer and model surgery on plaster dental cast, and fabrication of intermediate and final occlusal splint.
Study NCT03277443 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2D cephalometric radiograph
Description: 2D cephalometric radiograph
Study NCT03277443 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D computerized tomography
Description: 3D computerized tomography
Study NCT04234308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyglycolic Acid
Description: Periodontal and periimplant flaps closed with at least one suture with Polyglycolic Acid Absorbable suture, synthetic, 4-0. (TAGUM®).
Study NCT04234308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Catgut
Description: Periodontal and periimplant flaps closed with at least one suture with Chromic Gut Absorbable suture, natural, 4-0. (TAGUM®)
Study NCT04234308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polytetrafluoroethylene
Description: Periodontal and periimplant flaps closed with at least one suture with expanded Polytetrafluoroethylene Non absorbable suture, synthetic, 4-0. (TAGUM®)
Study NCT04234308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyamide
Description: Periodontal and periimplant flaps closed with at least one suture with Nylon Non absorbable sutures, synthetic, 4-0. (TAGUM®)
Study NCT02839772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Current skin care regimen plus 2% glycerine added to soaking water
Study NCT02839772 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Current skin care regimen
Study NCT04949217 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inlay Bristow
Description: A modified Bristow procedure
Study NCT04949217 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bristow
Description: Traditional Bristow procedure
Study NCT03290378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: IV; 25 mg or 50 mg, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
Study NCT03290378 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV; Placebo, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
Study NCT04099745 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGM
Description: Continuous Glucose Monitoring System
Study NCT04099745 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FGM
Description: Flash glucose monitoring System
Study NCT03055624 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embosphere microparticles for prostate artery embolization
Description: Pelvic angiograms will be performed and microspheres delivered to the arteries supplying the prostate to alleviate symptoms of benign prostatic hyperplasia.
Study NCT01274702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual Reconstitutions Therapy
Study NCT01274702 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saccadic Eye Movement Training
Study NCT00810212 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PLF with autograft
Description: 6 subjects
Study NCT00810212 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PLF with NeoFuse
Description: 6 subjects low dose
Study NCT00810212 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PLF with NeoFuse
Description: 6 subjects medium dose
Study NCT00810212 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PLF with NeoFuse
Description: 6 subjects high dose
Study NCT04633317 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A pneumatic nebulizer
Description: Inhaled colistimethate sodium generated by a pneumatic nebulizer
Study NCT04633317 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A vibrating mesh nebulizer
Description: Inhaled colistimethate sodium generated by a vibrating mesh nebulizer
Study NCT03024502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPP-AF Gel 1%
Description: Administration intravaginal of EPP-AG Gel 1%, 1x/day, 7 days
Study NCT03024502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPP-AF Gel 2%
Description: Administration intravaginal of EPP-AG Gel 1%, 1x/day, 7 days
Study NCT03024502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clotrimazole
Description: Administration intravaginal of clotrimazol, 1x/day, 7 days
Study NCT00970346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OligoG CF-5/20
Description: Inhaled OligoG CF-5/20 will be given to healthy volunteers with different concentrations to test tolerability of the drug
Study NCT04867005 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Impact of a training program
Description: Measurement of the effectiveness of a training program based on the skills and knowledge learning on advance care planning. A 10 hours online course was administered to both arms through an online platform; the 6 hours face-to-face course was administered to each primary care team (5) included in this arm. The 6 hours course was split into 2 sessions of 3 hours each.
Study NCT04867005 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Impact of a training program
Description: Measurement of the effectiveness of a training program based on the skills and knowledge learning on advance care planning. A 10 hours online course was administered to both arms through an online platform; the 6 hours face-to-face course was administered to each primary care team (5) included in this arm. The 6 hours course was split into 2 sessions of 3 hours each.
Study NCT01473914 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low dose: supplemental zinc, selenium and vitamin E
Description: 1. ZINC 25mg (AS ZINC SULFATE)~2. SELENIUM 50 mcg (AS SODIUM SELENITE)~3. VITAMIN E (D-ALPHA-TOCOPHEROL) (AS SUCCINATE) 250 IU
Study NCT01473914 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard renal vitamin: B and C renal vitamin
Description: 1. BIOTIN 300 MCG~2. D-PANTOTHENIC ACID (CALCIUM D-PANTOTHENATE) 10 MG~3. FOLIC ACID 1 MG~4. NIACINAMIDE 20 MG~5. VITAMIN B1 (THIAMINE MONONITRATE) 1.5 MG~6. VITAMIN B12(CYANOCOBALAMIN) 6 MCG~7. VITAMIN B2 (RIBOFLAVIN) 1.7 MG~8. VITAMIN B6 (PYRIDOXINE HYDROCHLORIDE) 10 MG~9. VITAMIN C (ASCORBIC ACID) 100 MG~10. INERT FILLER (CORNSTARCH)
Study NCT01473914 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard renal vitamin: B and C renal vitamin
Description: 1. BIOTIN 300 MCG~2. D-PANTOTHENIC ACID (CALCIUM D-PANTOTHENATE) 10 MG~3. FOLIC ACID 1 MG~4. NIACINAMIDE 20 MG~5. VITAMIN B1 (THIAMINE MONONITRATE) 1.5 MG~6. VITAMIN B12(CYANOCOBALAMIN) 6 MCG~7. VITAMIN B2 (RIBOFLAVIN) 1.7 MG~8. VITAMIN B6 (PYRIDOXINE HYDROCHLORIDE) 10 MG~9. VITAMIN C (ASCORBIC ACID) 100 MG~10. INERT FILLER (CORNSTARCH)
Study NCT03035500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive health education
Study NCT03035500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03035500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long-term Follow-up
Description: Undergo long-term follow-up using survivorship care plan
Study NCT03035500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03035500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01473914 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Medium dose: supplemental zinc, selenium and vitamin E
Description: 1. ZINC 50 mg (AS ZINC SULFATE)~2. SELENIUM 75 mcg (AS SODIUM SELENITE)~3. VITAMIN E (D-ALPHA-TOCOPHEROL) (AS SUCCINATE) 250 IU